SUPLASYN ישראל - עברית - Ministry of Health

suplasyn

דיפריס ושו'ת בע"מ - for the symptomatic treatment of osteoarthritis

Suplasyn 1 shot ישראל - עברית - Ministry of Health

suplasyn 1 shot

דיפריס ושו'ת בע"מ - רופא - for the symptomatic treatment of osteoarthritis

Corneal Topography ישראל - עברית - Ministry of Health

corneal topography

"אבנט ציוד רפואי בע""מ" - רופא - מכשיר למיפוי טופוגרפית לעיניים

Corneal Topography A ישראל - עברית - Ministry of Health

corneal topography a

אבנט ציוד רפואי בע"מ - רופא - מכשיר למיפוי טופוגרפית לעיניים

טבליס 100 מג ישראל - עברית - Ministry of Health

טבליס 100 מג

medison pharma ltd - fostamatinib as disodium hexahydrate - טבליות מצופות פילם - fostamatinib as disodium hexahydrate 100 mg - fostamatinib

טבליס 150 מג ישראל - עברית - Ministry of Health

טבליס 150 מג

medison pharma ltd - fostamatinib as disodium hexahydrate - טבליות מצופות פילם - fostamatinib as disodium hexahydrate 150 mg - fostamatinib

בינוקריט 1000 יחבל 0.5 מל ישראל - עברית - Ministry of Health

בינוקריט 1000 יחבל 0.5 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 1000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

בינוקריט 2000 יחבל 1 מל ישראל - עברית - Ministry of Health

בינוקריט 2000 יחבל 1 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 2000 iu / 1 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

בינוקריט 30000 יחבל 0.75 מל ישראל - עברית - Ministry of Health

בינוקריט 30000 יחבל 0.75 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 30000 iu / 0.75 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob